Early experience with sparfloxacin in tuberculosis.

Area of Science:

• Infectious Diseases
• Pulmonology
• Pharmacology

Background:

• Advanced tuberculosis (TB) presents significant treatment challenges, particularly in patients with extensive prior treatment histories.
• Exploring novel therapeutic agents is crucial for managing complex TB cases and improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of oral Sparfloxacin in patients with advanced tuberculosis.
• To assess the response to Sparfloxacin in various forms of advanced TB, including bone disease and meningitis.

Main Methods:

• A cohort of 14 advanced TB patients received oral Sparfloxacin 200 mg daily between December 1996 and July 1997.
• Sparfloxacin was administered in combination with various standard anti-TB drugs, including PAS, isoniazid, rifampicin, doxycycline, pyrazinamide, ethambutol, and streptomycin.
• Patient responses were monitored clinically, radiographically, and via sputum smear conversion.

Main Results:

• An early and dramatic clinical response was observed in most patients treated with Sparfloxacin.
• Twelve out of 14 patients showed good outcomes, with significant clinical improvement (11 patients), radiographic improvement exceeding 50% (11 patients), and sputum smear conversion (12 patients).
• The primary side effect reported was nausea; one patient with tuberculous meningitis did not survive despite initial improvement.

Conclusions:

• Oral Sparfloxacin demonstrated promising efficacy in treating advanced tuberculosis, including complex cases with abscesses and effusions.
• The drug was generally well-tolerated, with nausea being the main adverse event.
• Further investigation into Sparfloxacin's role in multidrug-resistant tuberculosis regimens may be warranted.